Reata Pharmaceuticals's Return on Invested Capital Insights

Loading...
Loading...

Benzinga Pro data, Reata Pharmaceuticals RETA reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last quarter. Reata Pharmaceuticals collected $7.39 million in revenue during Q3, but reported earnings showed a $71.85 million loss.

Why Is ROIC Significant?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q4, Reata Pharmaceuticals posted an ROIC of -22.7%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q4, Reata Pharmaceuticals posted an ROIC of -22.7%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Reata Pharmaceuticals, a negative ROIC ratio of -22.7% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Reata Pharmaceuticals reported Q4 earnings per share at $-1.59/share, which beat analyst predictions of $-2.31/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-ROCE
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...